Floatz logo

High Dose Lx2006

Extrinsic Cardiomyopathy

Explore 2 assets in Extrinsic Cardiomyopathy →
Floatz Rating
CCC48/100
Confidence
Indicative
v0.2
Sponsor
Lexeo Therapeutics
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05445323CT.gov
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Extrinsic Cardiomyopathy

AssetSponsorPhaseRating
High Dose Lx2006 (this asset)Lexeo TherapeuticsP1/2CCC · 48
Low Dose Lx2006Lexeo TherapeuticsP1/2CCC

Other indications for High Dose Lx2006

IndicationSponsorPhaseRating
Friedreich Ataxia—P1/2CC · 47

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. High Dose Lx2006 in Extrinsic Cardiomyopathy. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/high-dose-lx2006-extrinsic-cardiomyopathy

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →